REVB logo

Revelation Biosciences, Inc.

REVB
Healthcare|Biotechnology|US
$3.89
+0.33 (+9.27%)
DCF Value
$106.03
Tangible Book / Share
$12.93
Cash / Share
$16.30

About

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Stock Price

-86.2%(1Y)
1M
-28.2%
3M
-51.3%
6M
-42.1%
YTD
-82.6%
1Y
-86.6%
3Y
-100.0%
5Y
-100.0%

Pipeline Summary

1 total trials
1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 1

Key Facts

Market Cap$2.2M
Employees8 (+0% YoY)
CEOJames Rolke
IPO DateNov 17, 2020
Beta-0.17
52-Week Range$3.08 – $40.6
Avg Volume10,275
ExchangeNASDAQ

Ownership

Float76.5%
Shares Outstanding0.6M

Recent Insider Trades

Rolke JamesAWARD
Aug 17, 2026208,076 shares
Chawla Lakhmir SAWARD
Aug 17, 202632,011 shares
Zygmont Chester Stanley IIIGIFT
Aug 17, 2026208,073 shares
Zygmont Chester Stanley IIIAWARD
Aug 17, 2026208,073 shares
Zygmont Chester Stanley IIIGIFT
Aug 17, 2026208,073 shares

Peers

ATXIAvenue Therapeutics, Inc.
$1.4M
AZTRAzitra, Inc.
$4.4M
GTBPGT Biopharma, Inc.
$5.6M
INDPIndaptus Therapeutics, Inc.
$376.0M
NKGNNKGen Biotech, Inc.
$1.4M
ONCOOnconetix, Inc.
$2.5M
PBMPsyence Biomedical Ltd.
$56.3K
SLRXSalarius Pharmaceuticals, Inc.
$4.9M
Data last updated: Nov 9, 2026, 04:31 AM